Volition is a multi-national epigenetics company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers and other diseases. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid and is an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
In this video, chief executive officer Cameron Reynolds discusses the company’s fourth-quarter and full-year 2020 financial and operational results. Volition made significant progress with multiple programmes in 2020, culminating in the launch of its first product, the Nu.Q® Vet Cancer Screening Test. It has also made considerable progress in human studies with data released in blood cancer, lung cancer, Nu.Q® Capture, COVID-19 and, most recently, sepsis. Financially, the company is very well positioned, with cash and cash equivalents at 31 December 2020 totalling c US$19.4m.